KRYS vs. VERX
KRYS (Krystal Biotech, Inc.) and VERX (Vertex, Inc.) are both stocks. KRYS operates in Biotechnology (Healthcare), while VERX operates in Software - Application (Technology). Over the past 5 years, KRYS returned 37.14%/yr vs -6.85%/yr for VERX. At a 0.24 correlation, their price movements are largely independent.
Performance
KRYS vs. VERX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KRYS achieves a 22.42% return, which is significantly higher than VERX's -35.95% return.
KRYS
- 1D
- 2.94%
- 1M
- 5.18%
- YTD
- 22.42%
- 6M
- 38.79%
- 1Y
- 130.56%
- 3Y*
- 34.44%
- 5Y*
- 37.14%
- 10Y*
- —
VERX
- 1D
- -7.65%
- 1M
- -4.12%
- YTD
- -35.95%
- 6M
- -35.34%
- 1Y
- -68.70%
- 3Y*
- -16.19%
- 5Y*
- -6.85%
- 10Y*
- —
KRYS vs. VERX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
KRYS Krystal Biotech, Inc. | 22.42% | 57.37% | 26.28% | 56.60% | 13.25% | 16.58% | 45.00% |
VERX Vertex, Inc. | -35.95% | -62.57% | 98.03% | 85.67% | -8.57% | -54.46% | 45.63% |
Correlation
The correlation between KRYS and VERX is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.13 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.18 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.25 |
Correlation (All Time) Calculated using the full available price history since Jul 30, 2020 | 0.24 |
The correlation between KRYS and VERX shifts across timeframes, from 0.13 (1 year) to 0.25 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
KRYS:
$7.50
VERX:
-$0.05
KRYS:
21.71
VERX:
2.07
KRYS:
$417.30M
VERX:
$768.03M
KRYS:
$387.24M
VERX:
$486.52M
KRYS:
$185.45M
VERX:
$51.70M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KRYS vs. VERX — Risk / Return Rank
KRYS
VERX
KRYS vs. VERX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Krystal Biotech, Inc. (KRYS) and Vertex, Inc. (VERX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| KRYS | VERX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +4.56 | ||
| Sortino ratioReturn per unit of downside risk | +5.82 | ||
| Omega ratioGain probability vs. loss probability | 1.50 | 0.73 | +0.76 |
| Calmar ratioReturn relative to maximum drawdown | 8.24 | -0.93 | +9.17 |
| Martin ratioReturn relative to average drawdown | 21.37 | -1.32 | +22.69 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| KRYS | VERX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 3.38 | -1.18 | +4.56 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.49 | -0.13 | +0.62 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.63 | -0.18 | +0.82 |
Drawdowns
KRYS vs. VERX - Drawdown Comparison
The maximum KRYS drawdown since its inception was -53.42%, smaller than the maximum VERX drawdown of -81.68%. Use the drawdown chart below to compare losses from any high point for KRYS and VERX.
Loading charts...
Drawdown Indicators
| KRYS | VERX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -53.42% | -81.68% | +28.26% |
Max Drawdown (1Y)Largest decline over 1 year | -15.94% | -74.21% | +58.27% |
Max Drawdown (3Y)Largest decline over 3 years | -42.26% | -81.68% | +39.42% |
Max Drawdown (5Y)Largest decline over 5 years | -44.55% | -81.68% | +37.13% |
Current DrawdownCurrent decline from peak | -4.58% | -78.30% | +73.72% |
Average DrawdownAverage peak-to-trough decline | -16.22% | -42.24% | +26.02% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.13% | 51.97% | -45.84% |
Volatility
KRYS vs. VERX - Volatility Comparison
The current volatility for Krystal Biotech, Inc. (KRYS) is 10.26%, while Vertex, Inc. (VERX) has a volatility of 27.71%. This indicates that KRYS experiences smaller price fluctuations and is considered to be less risky than VERX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KRYS | VERX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.26% | 27.71% | -17.45% |
Volatility (6M)Calculated over the trailing 6-month period | 27.20% | 47.52% | -20.32% |
Volatility (1Y)Calculated over the trailing 1-year period | 39.04% | 58.61% | -19.57% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 76.43% | 54.49% | +21.94% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 74.23% | 55.71% | +18.52% |
Dividends
KRYS vs. VERX - Dividend Comparison
Neither KRYS nor VERX has paid dividends to shareholders.
Financials
KRYS vs. VERX - Financials Comparison
This section allows you to compare key financial metrics between Krystal Biotech, Inc. and Vertex, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
KRYS vs. VERX - Profitability Comparison
KRYS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Krystal Biotech, Inc. reported a gross profit of 110.03M and revenue of 116.36M. Therefore, the gross margin over that period was 94.6%.
VERX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Vertex, Inc. reported a gross profit of 124.87M and revenue of 196.65M. Therefore, the gross margin over that period was 63.5%.
KRYS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Krystal Biotech, Inc. reported an operating income of 53.69M and revenue of 116.36M, resulting in an operating margin of 46.1%.
VERX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Vertex, Inc. reported an operating income of -10.61M and revenue of 196.65M, resulting in an operating margin of -5.4%.
KRYS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Krystal Biotech, Inc. reported a net income of 55.93M and revenue of 116.36M, resulting in a net margin of 48.1%.
VERX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Vertex, Inc. reported a net income of -2.51M and revenue of 196.65M, resulting in a net margin of -1.3%.
Frequently Asked Questions
KRYS and VERX have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
VERX has higher volatility (27.71%) compared to KRYS (10.26%). In terms of maximum drawdown, KRYS dropped -53.42% vs VERX's -81.68%.
KRYS currently has the higher Sharpe Ratio (3.38 vs -1.18), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KRYS and VERX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer